Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy

Mostrar otras versiones (1)

BACKGROUND: Immuno-oncology (I-O) therapies target the host immune system, providing the potential to choose a uniform dose and schedule across tumor types. However, dose selection for I-O agents usually occurs early in clinical development and is typically based on tumor response, which may not ful...

Descripción completa

Detalles Bibliográficos
Autores principales: Agrawal, Shruti, Feng, Yan, Roy, Amit, Kollia, Georgia, Lestini, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109842/
https://www.ncbi.nlm.nih.gov/pubmed/27879974
http://dx.doi.org/10.1186/s40425-016-0177-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109842/
https://www.ncbi.nlm.nih.gov/pubmed/27879974
http://dx.doi.org/10.1186/s40425-016-0177-2

Ejemplares similares